Affiliation:
1. Department of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine , University of Belgrade , Belgrade , Serbia ;
2. Clinical Centre of Serbia, Institute for Orthopaedic Surgery and Traumatology , Belgrade , Serbia
Abstract
Abstract
Ketamine and magnesium can interact in additive, supra-additive and antagonistic manners in analgesia or anesthesia. Ketamine is a non-competitive NMDA receptor antagonist. Magnesium is an endogenous non-competitive NMDA antagonist that causes anion channel blockade in a dose-dependent manner. It has been established that ketamine and magnesium interact synergistically in the tail-immersion test in rats.
To determine the role of serotonergic, GABAergic and noradrenergic systems in analgesia induced by the ketamine-magnesium sulfate combination.
Experiments were performed on male Wistar albino rats (200-250 g). Antinociception was evaluated by the tail-immersion test.
Methysergide (0.5 and 1 mg/kg, sc) administered alone did not affect nociception in rats. Methysergide (0.5 and 1 mg/kg, sc) antagonized the antinociceptive effect of the ketamine (5 mg/kg)-magnesium sulfate (5mg/kg) combination. Bicuculline (0.5 and 1 mg/kg, sc) given alone did not change the threshold to thermal stimuli in rats. Bicuculline (0.5 and 1 mg/kg, sc) antagonized the antinociceptive effect of the ketamine (5 mg/kg)-magnesium sulfate (5 mg/kg) combination. Yohimbine (0.5, 1 and 3 mg/kg, sc) applied alone did not change nociception. Yohimbine at a dose of 0.5 mg/kg did not influence the effect of ketamine (5 mg/kg)-magnesium sulfate (5 mg/kg), while yohimbine at doses of 1 and 3 mg/kg antagonized the antinociceptive effect of this combination.
Serotonergic, noradrenergic and GABAergic systems participate, at least in part, in the antinociceptive effect of the ketamine-magnesium sulfate combination in acute pain in rats.
Reference42 articles.
1. 1. Wei H, Petrovaara A: MK-801, an NMDA receptor antagonist, in the rostroventromedial medulla attenuates development of neuropathic symptoms in the rat. Neroreport 1999, 10:2933-7.10.1097/00001756-199909290-00011
2. 2. Garraway SM, Hochman S: Pharmacological characterization of serotonin receptor subtypes modulating primary afferent input to deep dorsal horn neurons in the neonatal rat. Br J Pharmacol 2001, 132(8):1789-98.10.1038/sj.bjp.0703983
3. 3. Roczniak W, Wróbel J, Dolczak L, Nowak P: Influence of central noradrenergic system lesion on the serotoninergic 5-HT3 receptor mediated analgesia in rats. Adv Clin Exp Med 2013, 22(5):629-38.
4. 4. Dickenson AH, Chapman V, Green GM: The pharmacology of excitatory and inhibitory amino acid-mediated events in the transmission and modulation of pain in the spinal cord. Gen Pharmacol 1997, 28(5):633-8.10.1016/S0306-3623(96)00359-X
5. 5. Vaughan CW, Ingram SL, Connor MA, Christie MJ: How opioids inhibit GABA-mediated neurotransmission. Nature 1997, 390(6660):611-4.10.1038/37610
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献